Menu Search
Equities

Tryptamine Therapeutics Ltd

TYPTF:PKC

Tryptamine Therapeutics Ltd

Actions
  • Price (USD)0.025
  • Today's Change0.002 / 8.70%
  • Shares traded532.94k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:54 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.

  • Revenue in AUD (TTM)--
  • Net income in AUD--
  • Incorporated2013
  • Employees--
  • Location
    Tryptamine Therapeutics LtdC/o Bio101 Financial Advisory Pty LtdSuite 201, 697 Burke Road, CamberwellMELBOURNE 3124AustraliaAUS
  • Phone+61 38419-0827
  • Websitehttps://exopharm.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TYP:ASX since
announced		Transaction
value
TRYP Therapeutics IncDeal completed11 Dec 202311 Dec 2023Deal completed350.00%2.82m
Data delayed at least 20 minutes, as of Nov 22 2024 04:58 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.